Stock Screener App

Gratuito -

Installare

Drug Manufacturers - General

6.555

3.39% 0.215

Organon Co (OGN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Organon Co Borsa (OGN) Ultime notizie

The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media

Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN) - Insider Monkey

Co. (7XP) stock in 20252025 Sector Review & Safe Entry Point Alerts - newser.com

Organon (OGN) Price Target Decreased by 15.36% to 11.05 - Nasdaq

MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.

Organon & Co. (NYSE:OGN) Given Average Rating of "Hold" by Brokerages - MarketBeat

Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha

Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat

Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights

Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st

Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat

D.A. Davidson & CO. Sells 50,248 Shares of Organon & Co. $OGN - MarketBeat

Why Organon (OGN) Stock Is Down Today - TradingView

Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade

Organon hit hard over ousted CEO scandal - The Pharma Letter

The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha

Organon & Co. (NYSE:OGN) Hits New 52-Week Low After Analyst Downgrade - MarketBeat

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent

Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire

Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛

Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize

Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia

Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ

Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada

Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire

Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire

Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma

Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's

Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ

Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance

Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC

This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's

Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener

Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine

Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha

Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz

Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa

Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg.com

Organon appoints company executive Joseph Morrissey as interim CEO and board chair Carrie Cox as executive chair; announces results of audit committee investigation - MarketScreener

Organon Appoints Company Executive Joseph Morrissey As Interim CEO And Board Chair Carrie Cox As Executive Chair Announces Results Of Audit Committee Investigation - TradingView

Organon CEO Kevin Ali to resign after probe into contraceptive sales - Reuters

Organon CEO Kevin Ali Resigns Amid Audit Probe Into Wholesaler Sales Practices - Stocktwits

Organon & Co. Announces CEO Changes - MarketScreener

Organon stock tumbles after CEO resigns amid sales practice investigation By Investing.com - Investing.com UK

Organon falls as CEO resigns after probe into contraceptive sales - TradingView

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices - MarketScreener

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation - Stock Titan

Co. (7XP) stock considered safe havenMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com

Bleakley Financial Group LLC Acquires 68,873 Shares of Organon & Co. $OGN - MarketBeat

Organon & Co. (NYSE:OGN) Given Sell (D+) Rating at Weiss Ratings - MarketBeat

Allspring Global Investments Holdings LLC Lowers Holdings in Organon & Co. $OGN - MarketBeat

Co. (7XP) stock survive global slowdown2025 Sector Review & Safe Entry Point Alerts - newser.com

180 Wealth Advisors LLC Raises Stake in Organon & Co. $OGN - MarketBeat

Assessing Organon Stock After a 39.5% Drop and Recent Portfolio Moves - Yahoo Finance

Organon (OGN) Laps the Stock Market: Here's Why - sharewise.com

SNY

$50.89

0.38%

PFE

$24.49

0.79%

GILD

$119.78

0.94%

AMGN

$293.18

0.44%

NVO

$50.24

2.19%

MRK

$85.84

0.85%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters